There is emerging awareness that the clinical behavior of colon cancer is impacted by the specific site of origin within the colon: for example, with tumors on the right side are associated with reduced survival relative to left-sided CRCs, data from multiple clinical trials demonstrating that left-sided colon cancer patients are more responsive to anti-EGFR therapy than right-sided cancers47, and an ongoing investigation into whether different mutational spectra exist in left versus right colon44,48,49. The gene discussed is EGFR; the disease is malignant colon neoplasm.